GAAP EPS loss widened to $(0.41), reflecting higher R&D spending and no revenue. R&D expenses increased to $18.4 million (GAAP), compared to $14.6 million for Q2 2024, as PMV Pharmaceuticals advanced ...
PMV Pharmaceuticals, Inc. reported a corporate update and financial results for the first quarter of 2025, focusing on the ongoing Phase 2 PYNNACLE clinical trial evaluating rezatapopt, a treatment ...
First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Phase 1 ...
PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals (PMVP), Inc. , a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies ...
Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors ...
PMV Pharmaceuticals, Inc. has announced that its CEO, David H. Mack, and Chief Development Officer, Deepika Jalota, will participate in upcoming investor conferences, specifically the TD Cowen Annual ...
PRINCETON, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals (PMVP), Inc. , a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies ...
PMV Pharmaceuticals has pressed pause on two preclinical tumor candidates to funnel all resources into getting its lead precision oncology med through the clinic. The “primary focus” of PMV is now the ...
PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic ...
PRINCETON, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. ("PMV Pharma” or the "Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of ...
PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results